JP2013516489A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013516489A5 JP2013516489A5 JP2012548193A JP2012548193A JP2013516489A5 JP 2013516489 A5 JP2013516489 A5 JP 2013516489A5 JP 2012548193 A JP2012548193 A JP 2012548193A JP 2012548193 A JP2012548193 A JP 2012548193A JP 2013516489 A5 JP2013516489 A5 JP 2013516489A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- modified
- composition according
- compound
- modified oligonucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 108091034117 Oligonucleotide Proteins 0.000 claims 13
- 239000002777 nucleoside Substances 0.000 claims 11
- 150000001875 compounds Chemical class 0.000 claims 10
- 241001465754 Metazoa Species 0.000 claims 6
- 125000003835 nucleoside group Chemical group 0.000 claims 6
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 5
- 102100025668 Angiopoietin-related protein 3 Human genes 0.000 claims 4
- 101000693085 Homo sapiens Angiopoietin-related protein 3 Proteins 0.000 claims 4
- 230000002503 metabolic effect Effects 0.000 claims 3
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical group CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 208000016097 disease of metabolism Diseases 0.000 claims 2
- 208000030159 metabolic disease Diseases 0.000 claims 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 150000007523 nucleic acids Chemical group 0.000 claims 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29360410P | 2010-01-08 | 2010-01-08 | |
| US61/293,604 | 2010-01-08 | ||
| PCT/US2011/020606 WO2011085271A2 (en) | 2010-01-08 | 2011-01-07 | Modulation of angiopoietin-like 3 expression |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015156939A Division JP6440592B2 (ja) | 2010-01-08 | 2015-08-07 | アンジオポエチン様３発現の調節 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013516489A JP2013516489A (ja) | 2013-05-13 |
| JP2013516489A5 true JP2013516489A5 (cg-RX-API-DMAC7.html) | 2013-08-08 |
| JP5822845B2 JP5822845B2 (ja) | 2015-11-25 |
Family
ID=44306180
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012548193A Expired - Fee Related JP5822845B2 (ja) | 2010-01-08 | 2011-01-07 | アンジオポエチン様３発現の調節 |
| JP2015156939A Expired - Fee Related JP6440592B2 (ja) | 2010-01-08 | 2015-08-07 | アンジオポエチン様３発現の調節 |
| JP2017098842A Pending JP2017165765A (ja) | 2010-01-08 | 2017-05-18 | アンジオポエチン様３発現の調節 |
| JP2020032712A Pending JP2020100654A (ja) | 2010-01-08 | 2020-02-28 | アンジオポエチン様３発現の調節 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015156939A Expired - Fee Related JP6440592B2 (ja) | 2010-01-08 | 2015-08-07 | アンジオポエチン様３発現の調節 |
| JP2017098842A Pending JP2017165765A (ja) | 2010-01-08 | 2017-05-18 | アンジオポエチン様３発現の調節 |
| JP2020032712A Pending JP2020100654A (ja) | 2010-01-08 | 2020-02-28 | アンジオポエチン様３発現の調節 |
Country Status (9)
| Country | Link |
|---|---|
| US (5) | US8653047B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3421040A1 (cg-RX-API-DMAC7.html) |
| JP (4) | JP5822845B2 (cg-RX-API-DMAC7.html) |
| CN (3) | CN111700901A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2011203986C1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2786071C (cg-RX-API-DMAC7.html) |
| DK (1) | DK2521556T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2677969T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2011085271A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009323766B2 (en) | 2008-12-02 | 2016-10-06 | Wave Life Sciences Ltd. | Method for the synthesis of phosphorus atom modified nucleic acids |
| SG177564A1 (en) | 2009-07-06 | 2012-02-28 | Ontorii Inc | Novel nucleic acid prodrugs and methods of use thereof |
| WO2011085271A2 (en) | 2010-01-08 | 2011-07-14 | Isis Pharmaceuticals, Inc. | Modulation of angiopoietin-like 3 expression |
| EP2620428B1 (en) | 2010-09-24 | 2019-05-22 | Wave Life Sciences Ltd. | Asymmetric auxiliary group |
| AR087329A1 (es) | 2011-06-17 | 2014-03-19 | Regeneron Pharma | Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana |
| CA2839573A1 (en) * | 2011-06-21 | 2012-12-27 | Alnylam Pharmaceuticals, Inc. | Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof |
| US9605019B2 (en) | 2011-07-19 | 2017-03-28 | Wave Life Sciences Ltd. | Methods for the synthesis of functionalized nucleic acids |
| EP3640332A1 (en) | 2011-08-29 | 2020-04-22 | Ionis Pharmaceuticals, Inc. | Oligomer-conjugate complexes and their use |
| HRP20191883T1 (hr) * | 2011-11-07 | 2019-12-27 | Ionis Pharmaceuticals, Inc. | Modulacija ekspresije tmprss6 |
| IL303831A (en) * | 2011-11-18 | 2023-08-01 | Alnylam Pharmaceuticals Inc | Adapted RNAI factors |
| JP6246121B2 (ja) | 2012-07-13 | 2017-12-13 | 株式会社新日本科学 | キラル核酸アジュバント |
| JP6268157B2 (ja) | 2012-07-13 | 2018-01-24 | 株式会社Ｗａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｊａｐａｎ | 不斉補助基 |
| SG10201912895PA (en) | 2012-07-13 | 2020-02-27 | Wave Life Sciences Ltd | Chiral control |
| ES2724853T3 (es) | 2012-11-15 | 2019-09-16 | Roche Innovation Ct Copenhagen As | Conjugados de oligonucleótidos |
| MY177989A (en) | 2013-01-30 | 2020-09-28 | Hoffmann La Roche | Lna oligonucleotide carbohydrate conjugates |
| KR102138781B1 (ko) | 2013-05-01 | 2020-07-28 | 아이오니스 파마수티컬즈, 인코포레이티드 | 아포지질단백질 c-iii 발현을 조절하는 조성물 및 방법 |
| TWI772856B (zh) * | 2013-07-19 | 2022-08-01 | 美商百健Ｍａ公司 | 用於調節τ蛋白表現之組合物 |
| DK3087183T3 (da) * | 2013-12-24 | 2020-09-14 | Ionis Pharmaceuticals Inc | Modulation af angiopoietin-3-lignende ekspression |
| JPWO2015108047A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤 |
| JPWO2015108048A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
| EP3095460A4 (en) | 2014-01-15 | 2017-08-23 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent |
| PT3094728T (pt) | 2014-01-16 | 2022-05-19 | Wave Life Sciences Ltd | Desenho quiral |
| US9382540B2 (en) * | 2014-05-01 | 2016-07-05 | Isis Pharmaceuticals, Inc | Compositions and methods for modulating angiopoietin-like 3 expression |
| WO2015179693A1 (en) | 2014-05-22 | 2015-11-26 | Isis Pharmaceuticals, Inc. | Conjugated antisense compounds and their use |
| US20180245077A1 (en) * | 2015-03-20 | 2018-08-30 | Protiva Biotherapeutics, Inc. | Compositions and methods for treating hypertriglyceridemia |
| HK1249140A1 (zh) | 2015-04-03 | 2018-10-26 | Ionis Pharmaceuticals, Inc. | 用於调节tmprss6表达的化合物和方法 |
| TWI862799B (zh) | 2015-04-13 | 2024-11-21 | 美商阿尼拉製藥公司 | 類血管生成素３（ＡＮＧＰＴＬ３）ｉＲＮＡ組成物及其用途方法 |
| KR20250078597A (ko) | 2015-11-06 | 2025-06-02 | 아이오니스 파마수티컬즈, 인코포레이티드 | 아포리포프로테인 (a) 발현 조정 |
| CA3000016A1 (en) * | 2015-11-06 | 2017-05-11 | Gemphire Therapeutics Inc. | Gemcabene combinations for the treatment of cardiovascular disease |
| LT4119569T (lt) | 2015-11-06 | 2024-09-25 | Ionis Pharmaceuticals, Inc. | Konjuguoti priešprasmiai junginiai, skirti panaudoti terapijoje |
| SMT202300219T1 (it) * | 2016-02-17 | 2023-09-06 | Regeneron Pharma | Metodi per il trattamento o la prevenzione dell’aterosclerosi mediante somministrazione di un inibitore di angptl3 |
| JP7541810B2 (ja) | 2016-03-03 | 2024-08-29 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ａｎｇｐｔｌ３阻害剤と組み合わせてｐｃｓｋ９阻害剤を投与することにより高脂血症を有する患者を処置するための方法 |
| US10961271B2 (en) * | 2016-03-16 | 2021-03-30 | Ionis Pharmaceuticals, Inc. | Methods of modulating KEAP1 |
| LT3448426T (lt) * | 2016-04-28 | 2025-07-10 | Regeneron Pharmaceuticals, Inc. | Pacientų, sergančių šeimine hipercholesterolemija, gydymo būdai |
| SG11201809002RA (en) | 2016-04-29 | 2018-11-29 | Univ Nanyang Tech | G-quadruplex-containing antisense oligonucleotides |
| EP3475424A1 (en) | 2016-06-22 | 2019-05-01 | ProQR Therapeutics II B.V. | Single-stranded rna-editing oligonucleotides |
| CN110352244B (zh) * | 2016-09-01 | 2023-03-21 | ProQR治疗上市公司Ⅱ | 化学修饰的编辑rna的单链寡核苷酸 |
| JP2019535839A (ja) | 2016-11-29 | 2019-12-12 | ピュアテック ヘルス エルエルシー | 治療剤の送達のためのエクソソーム |
| CN108220293B (zh) * | 2016-12-21 | 2021-09-24 | 苏州瑞博生物技术股份有限公司 | 一种小干扰核酸和药物组合物及其用途 |
| EP3571300A1 (en) | 2017-01-19 | 2019-11-27 | ProQR Therapeutics II B.V. | Oligonucleotide complexes for use in rna editing |
| EP3678273A4 (en) | 2017-08-30 | 2021-01-06 | Kyocera Corporation | POWER SUPPLY MANAGEMENT PROCESS AND POWER SUPPLY MANAGEMENT DEVICE |
| MX2020001912A (es) * | 2017-09-14 | 2020-03-24 | Arrowhead Pharmaceuticals Inc | Agentes de iarn y composiciones para inhibir la expresion de la angiopoyetina tipo 3 (angptl3) y metodos de uso. |
| JP7727308B2 (ja) | 2017-12-01 | 2025-08-21 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 二本鎖オリゴヌクレオチド、二本鎖オリゴヌクレオチドを含む組成物および複合体ならびに調製方法と使用 |
| US12083142B2 (en) | 2017-12-01 | 2024-09-10 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof |
| JP7273417B2 (ja) | 2017-12-01 | 2023-05-15 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、当該核酸を含む組成物および複合体ならびに調製方法と使用 |
| JP7365052B2 (ja) | 2017-12-01 | 2023-10-19 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用 |
| US11414661B2 (en) | 2017-12-01 | 2022-08-16 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof |
| DK3732185T3 (da) | 2017-12-29 | 2025-03-31 | Suzhou Ribo Life Science Co Ltd | Konjugater og fremstilling og anvendelse heraf |
| GB201808146D0 (en) | 2018-05-18 | 2018-07-11 | Proqr Therapeutics Ii Bv | Stereospecific Linkages in RNA Editing Oligonucleotides |
| US11918600B2 (en) | 2018-08-21 | 2024-03-05 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition and conjugate containing nucleic acid, and use thereof |
| CN111655297A (zh) | 2018-09-30 | 2020-09-11 | 苏州瑞博生物技术有限公司 | 一种siRNA缀合物及其制备方法和用途 |
| BR112021009054A2 (pt) * | 2018-11-13 | 2021-08-24 | Lipigon Pharmaceuticals Ab | Oligonucleotídeos angptl4 influenciando a regulação do metabolismo de ácido graxo |
| CN112423795A (zh) * | 2018-12-28 | 2021-02-26 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| EP3903830A4 (en) | 2018-12-28 | 2023-04-26 | Suzhou Ribo Life Science Co., Ltd. | NUCLEIC ACID, COMPOSITION AND CONJUGATE WITH NUCLEIC ACID, PROCESS FOR THEIR PREPARATION AND ITS USE |
| EP3908287A1 (en) * | 2019-01-08 | 2021-11-17 | Avogadro Development Corp. | Treatment of fatty liver disease |
| AU2020280438B2 (en) | 2019-05-22 | 2025-03-06 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use |
| CN111973617A (zh) * | 2019-05-23 | 2020-11-24 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| EP4223875A1 (en) * | 2020-09-30 | 2023-08-09 | Nanopeptide (Qingdao) Biotechnology Ltd. | Sirna of angiopoietin-like 3 (angptl3) and use thereof |
| IL305414A (en) | 2021-03-04 | 2023-10-01 | Alnylam Pharmaceuticals Inc | Angiopoietin-like 3 (ANGPTL3) IRNA compositions and methods of using them |
| AU2022298603A1 (en) * | 2021-06-21 | 2024-02-01 | Shanghai Junshi Biosciences Co., Ltd. | Sirna inhibiting angptl3 gene expression, and use thereof |
| MX2024007900A (es) | 2021-12-22 | 2024-07-10 | Regeneron Pharma | Tratamiento de enfermedades renales con inhibidores de la angiopoyetina tipo 3 (angptl3). |
| WO2023134705A1 (zh) * | 2022-01-11 | 2023-07-20 | 上海金中锘美生物医药科技有限公司 | 抑制angptl3表达的rna干扰剂及其用途 |
| WO2024032608A1 (zh) * | 2022-08-08 | 2024-02-15 | 大睿生物医药科技(上海)有限公司 | 调控ANGPTL3基因活性的siRNA分子 |
| AU2023375521A1 (en) | 2022-11-10 | 2025-05-15 | Regeneron Pharmaceuticals, Inc. | Treatment of kidney diseases with a combination of angiopoietin like 3 (angptl3) inhibitors and solute carrier family 5 member 2 (slc5a2) inhibitors |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2699808A (en) | 1944-10-06 | 1955-01-18 | Mark W Lowe | Apparatus for peeling tomatoes |
| US2699508A (en) | 1951-12-21 | 1955-01-11 | Selectronics Inc | Method of mounting and construction of mounting for low frequency piezoelectric crystals |
| US6582908B2 (en) | 1990-12-06 | 2003-06-24 | Affymetrix, Inc. | Oligonucleotides |
| JPH08504559A (ja) | 1992-12-14 | 1996-05-14 | ハネウエル・インコーポレーテッド | 個別に制御される冗長巻線を有するモータシステム |
| US5801154A (en) | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| US5656408A (en) | 1996-04-29 | 1997-08-12 | Xerox Corporation | Coated carrier particles |
| US7875733B2 (en) | 2003-09-18 | 2011-01-25 | Isis Pharmaceuticals, Inc. | Oligomeric compounds comprising 4′-thionucleosides for use in gene modulation |
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| US6770748B2 (en) | 1997-03-07 | 2004-08-03 | Takeshi Imanishi | Bicyclonucleoside and oligonucleotide analogue |
| JP4236812B2 (ja) | 1997-09-12 | 2009-03-11 | エクシコン エ／エス | オリゴヌクレオチド類似体 |
| US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
| US20030228597A1 (en) | 1998-04-13 | 2003-12-11 | Cowsert Lex M. | Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation |
| JP2002524506A (ja) * | 1998-09-15 | 2002-08-06 | ビーティージー・インターナショナル・リミテッド | 治療用組成物（ｉｉ） |
| CN102180924A (zh) | 1999-05-04 | 2011-09-14 | 桑塔里斯制药公司 | L-核糖-lna类似物 |
| US6525191B1 (en) | 1999-05-11 | 2003-02-25 | Kanda S. Ramasamy | Conformationally constrained L-nucleosides |
| EP1210363A2 (en) * | 1999-07-16 | 2002-06-05 | Hyseq, Inc. | Novel angiopoietin materials and methods |
| CA2390676A1 (en) * | 1999-12-09 | 2001-06-14 | Sankyo Company, Limited | Method of testing remedy or preventive for hyperlipemia |
| WO2002101039A1 (fr) | 2001-06-08 | 2002-12-19 | Sankyo Company, Limited | Procede de test de medicament destine a traiter ou a prevenir des maladies telles que l'hyperlipemie |
| WO2003004602A2 (en) | 2001-07-03 | 2003-01-16 | Isis Pharmaceuticals, Inc. | Nuclease resistant chimeric oligonucleotides |
| CA2464542C (en) * | 2001-11-16 | 2015-01-20 | Genentech, Inc. | Composition comprising and method of using angiopoietin-like protein 3 angptl3 |
| US8604183B2 (en) | 2002-11-05 | 2013-12-10 | Isis Pharmaceuticals, Inc. | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
| EP1562971B1 (en) | 2002-11-05 | 2014-02-12 | Isis Pharmaceuticals, Inc. | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
| US7511131B2 (en) * | 2002-11-13 | 2009-03-31 | Genzyme Corporation | Antisense modulation of apolipoprotein B expression |
| WO2006006948A2 (en) | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
| EP2314691A3 (en) | 2002-11-14 | 2012-01-18 | Dharmacon, Inc. | Fuctional and hyperfunctional siRNA |
| WO2004072046A2 (en) | 2003-02-12 | 2004-08-26 | Carex S.A. | Quinoline derivatives and their use for modulation of lxr activity |
| WO2004106356A1 (en) | 2003-05-27 | 2004-12-09 | Syddansk Universitet | Functionalized nucleotide derivatives |
| CA2536324A1 (en) | 2003-08-22 | 2005-03-10 | Nihon University | Hepatocellular cancer-associated gene |
| US7427672B2 (en) | 2003-08-28 | 2008-09-23 | Takeshi Imanishi | Artificial nucleic acids of n-o bond crosslinkage type |
| US7468431B2 (en) * | 2004-01-22 | 2008-12-23 | Isis Pharmaceuticals, Inc. | Modulation of eIF4E-BP2 expression |
| JP2007532135A (ja) * | 2004-04-13 | 2007-11-15 | アリーナ ファーマシューティカルズ， インコーポレイテッド | 高血糖症および関連障害の処置のための、ヒトｇタンパク質共役レセプターおよびそのモジュレーター |
| CN101052717A (zh) | 2004-05-11 | 2007-10-10 | α基因株式会社 | 诱发rna干扰的多核苷酸以及使用该多核苷酸的基因表达抑制方法 |
| AU2005269758B2 (en) * | 2004-07-20 | 2011-11-03 | Genentech, Inc. | Compositions and methods of using angiopoietin-like 4 protein |
| EP1771474B1 (en) | 2004-07-20 | 2010-01-27 | Genentech, Inc. | Inhibitors of angiopoietin-like 4 protein, combinations, and their use |
| CA2580504C (en) * | 2004-09-17 | 2013-10-29 | Isis Pharmaceuticals, Inc. | Enhanced antisense oligonucleotides |
| US20060147894A1 (en) | 2004-12-30 | 2006-07-06 | Vicam, L.P. | Jacketed vessel for holding semen for sex biasing mammals through artificial insemination and systems and methods for enhancing the probability of sex biasing using the same |
| CN102908630B (zh) | 2006-01-27 | 2014-11-19 | Isis制药公司 | 6-修饰的双环核酸类似物 |
| EP2015758B1 (en) * | 2006-05-05 | 2014-04-02 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating expression apob |
| EP2066684B1 (en) | 2006-05-11 | 2012-07-18 | Isis Pharmaceuticals, Inc. | 5'-modified bicyclic nucleic acid analogs |
| CA2660052A1 (en) | 2006-08-04 | 2008-02-07 | Isis Pharmaceuticals, Inc. | Compositions and methods for the modulation of jnk proteins |
| US8093222B2 (en) * | 2006-11-27 | 2012-01-10 | Isis Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia |
| CN101589143A (zh) * | 2006-11-27 | 2009-11-25 | Isis药物公司 | 用于治疗高胆固醇血症的方法 |
| ZA200904022B (en) | 2006-12-08 | 2010-08-25 | Lexicon Pharmaceuticals Inc | Monoclonal antibodies against ANGPTL3 |
| EP2125852B1 (en) | 2007-02-15 | 2016-04-06 | Ionis Pharmaceuticals, Inc. | 5'-substituted-2'-f modified nucleosides and oligomeric compounds prepared therefrom |
| CA2717618A1 (en) | 2008-03-07 | 2009-09-11 | National University Corporation University Of Toyama | Homologous recombination method, cloning method, and kit |
| JP5207355B2 (ja) | 2008-03-12 | 2013-06-12 | 凸版印刷株式会社 | 標的ヌクレオチド配列を有する核酸の検出方法、プローブセット、及び核酸の識別方法 |
| WO2009148605A2 (en) | 2008-06-04 | 2009-12-10 | Isis Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia |
| AT507215B1 (de) | 2009-01-14 | 2010-03-15 | Boehler Edelstahl Gmbh & Co Kg | Verschleissbeständiger werkstoff |
| WO2011085271A2 (en) * | 2010-01-08 | 2011-07-14 | Isis Pharmaceuticals, Inc. | Modulation of angiopoietin-like 3 expression |
| US9984408B1 (en) | 2012-05-30 | 2018-05-29 | Amazon Technologies, Inc. | Method, medium, and system for live video cooperative shopping |
| EP2733390B1 (en) | 2012-11-15 | 2020-05-13 | Volvo Car Corporation | Dampening structure for gear shift cables |
| US10120707B2 (en) | 2015-12-08 | 2018-11-06 | Paypal, Inc. | Deployment of development environments |
| US9778708B1 (en) | 2016-07-18 | 2017-10-03 | Lenovo Enterprise Solutions (Singapore) Pte. Ltd. | Dual sided latching retainer for computer modules |
-
2011
- 2011-01-07 WO PCT/US2011/020606 patent/WO2011085271A2/en not_active Ceased
- 2011-01-07 CN CN202010636959.XA patent/CN111700901A/zh active Pending
- 2011-01-07 ES ES11732249.5T patent/ES2677969T3/es active Active
- 2011-01-07 EP EP18174926.8A patent/EP3421040A1/en not_active Withdrawn
- 2011-01-07 DK DK11732249.5T patent/DK2521556T3/en active
- 2011-01-07 US US13/520,997 patent/US8653047B2/en active Active
- 2011-01-07 CA CA2786071A patent/CA2786071C/en active Active
- 2011-01-07 JP JP2012548193A patent/JP5822845B2/ja not_active Expired - Fee Related
- 2011-01-07 CN CN201180008657.7A patent/CN102753186B/zh not_active Expired - Fee Related
- 2011-01-07 CN CN201610643333.5A patent/CN106146591B/zh not_active Expired - Fee Related
- 2011-01-07 EP EP11732249.5A patent/EP2521556B1/en active Active
- 2011-01-07 AU AU2011203986A patent/AU2011203986C1/en not_active Ceased
-
2014
- 2014-01-07 US US14/149,715 patent/US9139831B2/en active Active
-
2015
- 2015-08-07 JP JP2015156939A patent/JP6440592B2/ja not_active Expired - Fee Related
- 2015-08-10 US US14/821,982 patent/US20160060626A1/en not_active Abandoned
-
2017
- 2017-05-18 JP JP2017098842A patent/JP2017165765A/ja active Pending
-
2018
- 2018-01-12 US US15/870,306 patent/US20180142244A1/en not_active Abandoned
-
2019
- 2019-12-20 US US16/722,043 patent/US11225664B2/en active Active
-
2020
- 2020-02-28 JP JP2020032712A patent/JP2020100654A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013516489A5 (cg-RX-API-DMAC7.html) | ||
| JP2012029693A5 (cg-RX-API-DMAC7.html) | ||
| Wu et al. | Long noncoding RNA Meg3 regulates cardiomyocyte apoptosis in myocardial infarction | |
| JP2014513954A5 (cg-RX-API-DMAC7.html) | ||
| JP2013518605A5 (cg-RX-API-DMAC7.html) | ||
| Tian et al. | Brahma‐related gene 1 bridges epigenetic regulation of proinflammatory cytokine production to steatohepatitis in mice | |
| RU2501803C2 (ru) | Композиции и способы модуляции экспрессии рецептора фактора роста фибробластов 4 (fgfr4) | |
| JP2014511686A5 (cg-RX-API-DMAC7.html) | ||
| IL264288A (en) | Methods and compositions for modulating apolipoprotein(a) expression | |
| JP2017533721A5 (cg-RX-API-DMAC7.html) | ||
| RU2015151199A (ru) | Сопряженные антисмысловые соединения и их применение | |
| FI2906696T4 (fi) | Menetelmiä c9orf72:n ilmentymisen moduloimiseksi | |
| JP2017510271A5 (cg-RX-API-DMAC7.html) | ||
| NZ710192A (en) | Modulation of apolipoprotein ciii (apociii) expression | |
| JP2015536132A5 (cg-RX-API-DMAC7.html) | ||
| IL300119A (en) | Oligonucleotides for inducing paternal ube3a expression | |
| RU2015119409A (ru) | Конъюгаты олигонуклеотидов | |
| NO2019001I1 (no) | Forbindelse omfattende et modifisert oligonukleotid som har en nukleobasesekvens bestående av 20 koblede nukleosider ifølge EP B1 2563920 krav 1 (SEQ ID NO: 80), hvor det modifiserte oligonukleotidet omfatter: et avstandssegment bestående av ti koblede deoksynukleosider; et 5'-vingesegment bestående av fem koblede nukleosider; og et 3'-vingesegment bestående av fem koblede nukleosider; hvor avstandssegmentet er plassert mellom 5'-vingesegmentet og 3'-vingesegmentet, hvor hvert nukleosid av hvert vingesegment omfatter et 2'-0-metoksyetylsukker; hvor hver cytosin av det modifiserte oligonukleotid er en 5-metylcytosin, og hvor hver internukleosid-binding av det modifiserte oligonukleotid er en fosfortioatbinding; og spesielt inotersen; og dets derivater, så som dets salter, inkludert natriumsalter. | |
| JP2013226147A5 (cg-RX-API-DMAC7.html) | ||
| JP2015507625A5 (cg-RX-API-DMAC7.html) | ||
| JP2012050438A5 (cg-RX-API-DMAC7.html) | ||
| JP2009508527A5 (cg-RX-API-DMAC7.html) | ||
| JP2017509354A5 (cg-RX-API-DMAC7.html) | ||
| JP2016096826A5 (cg-RX-API-DMAC7.html) | ||
| HRP20130766T1 (hr) | Mikrornk (mirnk) mir-21 za dijagnostiäśke i terapijske svrhe |